
Lupin Limited has informed the Exchange regarding a press release dated August 24, 2021, titled "Lupin Launches Luforbec�� 100/6 μg pMDI, first branded generic alternative to Fostair�� 100/6 μg pMDI for treatment of Asthma & COPD, in the UK.".
Filed with NSE ·

Lupin Limited has informed the Exchange regarding a press release dated August 24, 2021, titled "Lupin Launches Luforbec�� 100/6 μg pMDI, first branded generic alternative to Fostair�� 100/6 μg pMDI for treatment of Asthma & COPD, in the UK.".
6ix hasn’t read this filing yet.
Follow Lupin into a list and get an email when it puts out news.
Follow Lupin